Masimo Personal Health (MASI) - Multiplikator forward rega marang pendapatan
Masimo Corporation (MASI) dominates non-invasive monitoring, generating a steady cash flow through the sale of disposable sensors. The GURU.Markets portal features a price chart where the expected P/S ratio, with a value of 1.30 reflecting the latest metric level, correlates with this capacity. However, patent wars with tech giants and a painful exit from the audio segment create volatility, impacting the market value of the shares.
Masimo Inc. - rincian analitis lan metrik utama (MASI)
- rega pasar lan target rega analis:
- indikator kapitalisasi pasar:
- rincian valuasi buku bisnis:
- indikator beban kredit lan likuiditas emiten:
Utang marang Ekuitas Masimo Corporation|MASI - Rasio utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Masimo Corporation|MASI - Tanggungan utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku Masimo Inc.|MASI - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan Masimo|Rasio cepet masimo.com
- data bathi bisnis lan rasio investasi:
MASI - Bathi resik|Bathi sing dikarepake Masimo Corporation|MASI - Periode bali modal bisnis|Pangali Forward P/E Masimo Personal Health|MASI - Kapitalisasi marang bathi resik kanthi nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Masimo Inc.|MASI - Bathi operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Masimo|MASI - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan masimo.com|MASI - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Masimo Corporation
- data dodolan lan asil:
Analisis umum perusahaan:MASI (Masimo)
The Masimo Corporation business model is based on scalability driven by recurring sales of consumables for installed medical equipment. By analyzing the expected P/S ratio, an investor assesses the relationship between current market capitalization and projected revenue, which allows for determining the extent of the premium paid for future sales growth and synchronizing the entry point with the long-term market consensus on asset valuation.
Analisis perusahaan pesaing
Rasio rega marang prakiraan pendapatan Intuitive ISRG|Rega forward marang dodolan DHR|BDX: Multiplikator forward rega marang pendapatan|STE - Multiplikator Forward P/S|West Pharmaceutical Services (WST) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan baxter.com|STVN (Stevanato Group) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Teleflex Inc. TFX|Rasio rega marang prakiraan pendapatan Merit Medical Systems Inc (MMSI)|Nobel Biocare - Kapitalisasi marang prakiraan pendapatan|ICU Medical, Inc. - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake XRAY (dentsplysirona.com)|LMAT - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake AtriCure Inc ATRC|STAAR Surgical Corp (STAA) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan Niagen|ZIMV (ZimVie Inc.) - Multiplikator Forward P/S|Multiplikator Forward P/S angiodynamics.com|Rasio rega marang prakiraan pendapatan Cerus (CERS)|Rasio kapitalisasi marang dodolan sing dikarepake Alpha Teknova|Multiplikator Forward P/S MGRM (Monogram Technologies Inc)|Rasio kapitalisasi marang dodolan sing dikarepake Sharps Technology Inc (STSS)|INFU - Rasio rega marang prakiraan pendapatan|utahmed.com (UTMD) - Multiplikator forward rega marang pendapatan|korumedical.com (KRMD) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Nyxoah SA (NYXH)|Multiplikator forward rega marang pendapatan MBOT|PDEX: Rega forward marang dodolan|Multiplikator Forward P/S ZTEK|Multiplikator forward rega marang pendapatan elutia.com ELUT|Rasio rega marang prakiraan pendapatan Milestone Scientific Inc. MLSS|NEXGEL Inc. (NXGL) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|RVP - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan HBIO (harvardbioscience.com)|Femasys Inc. (FEMY) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan MHUA (Meihua Medical Technologies Co., Ltd.)|Rasio rega marang prakiraan pendapatan Predictive Oncology Inc|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Callan JMB Corp CJMB|Rasio rega marang prakiraan pendapatan Atrion Corp (ATRI)|NURO (NeuroMetrix Corporation) - Rega forward marang dodolan
